Arpan Banerjee at the 21st Annual Meeting of Oligonucleotide Therapeutics Society (OTS)
10/27/2025"It’s been an incredible experience attending the Oligonucleotide Therapeutics Society (OTS) 2025 Annual Meeting for the first time! It was amazing to see and be part of such a diverse range of cutting-edge work on oligonucleotides under one roof," Arpan sums up his visit in Budapest.
From 19 to 22 October, leading researchers and industry experts gathered in Budapest to discuss the future of oligonucleotide therapeutics. Arpan, PhD student at Höbartner Lab had the opportunity to present a part of his PhD work with the poster “Morpholino-Modified Ribozymes: Stabilizing Catalytic RNAs in Cellular Environments” and to discuss his research with so many inspiring scientists, entrepreneurs, and fellow RNA enthusiasts.
“It was also a pleasure to meet and network with brilliant minds across the oligonucleotide therapeutics community — from chemists to clinical scientists also during the Annual Wrap-up Party on the last day,” Arpan summarises. “An experience that would not have been possible without the continuous guidance of Prof. Claudia Höbartner and the support of the Boehringer Ingelheim Fund.”
The Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) as a premier event brings together experts to exchange ideas and advance knowledge across diverse areas such as antisense, siRNA, immunostimulatory, and aptamer technologies, alongside RNA/DNA editing and mRNA therapeutics. Participants—from established scientists and companies to emerging researchers—can engage in thought-provoking discussions, share cutting-edge findings, and connect with colleagues in the field.
Additional images
